CAJ | 학술논문

目的：回顾性分析尼妥珠单抗治疗晚期非小细胞肺癌（NSCLC）的临床疗效及不良反应。方法纳入15例经病理组织学或细胞学检查确诊的Ⅳ期NSCLC患者，其中腺癌9例，鳞状细胞癌8例。所有患者均接受尼妥珠单抗治疗（尼妥珠单抗400 mg ，静脉滴注，每周1次）。每治疗6周后按照实体瘤疗效评价标准（RECIST）进行疗效评价，按照NCI-CTC 3.0标准评价不良反应。结果15例患者均可评价药物安全性，其中11例可评价药物的客观疗效。在这11例患者中，疾病稳定（SD）8例，病情进展（PD）3例，疾病控制率为72.7％（8/11）；药物安全性评价结果显示尼妥珠单抗治疗相关的皮疹发生率低，且与临床获益无关；与尼妥珠单抗相关的不良反应轻。结论尼妥珠单抗联合化疗或放化疗能提高晚期NSCLC患者的疾病控制率，并且总体不良反应较轻。
목적：회고성분석니타주단항치료만기비소세포폐암（NSCLC）적림상료효급불량반응。방법납입15례경병리조직학혹세포학검사학진적Ⅳ기NSCLC환자，기중선암9례，린상세포암8례。소유환자균접수니타주단항치료（니타주단항400 mg ，정맥적주，매주1차）。매치료6주후안조실체류료효평개표준（RECIST）진행료효평개，안조NCI-CTC 3.0표준평개불량반응。결과15례환자균가평개약물안전성，기중11례가평개약물적객관료효。재저11례환자중，질병은정（SD）8례，병정진전（PD）3례，질병공제솔위72.7％（8/11）；약물안전성평개결과현시니타주단항치료상관적피진발생솔저，차여림상획익무관；여니타주단항상관적불량반응경。결론니타주단항연합화료혹방화료능제고만기NSCLC환자적질병공제솔，병차총체불량반응교경。
Objective To retrospectively analyze the therapeutic efficacy and adverse events of nimotuzumab in advanced non-small cell lung cancer (NSCLC). Method Nimotuzumab was administrated to 15 cases of stage IV NSCLC, including 9 cases of adenocarcinoma and 8 cases of squamous cell carcinoma. All patients were confirmed by either histopathology or cytopathology, and were treated by nimotzumab (nimotuzumab 400 mg, i.v., qw). The ef-ficacy was evaluated after six weeks of treatment according to RECIST standards. For adverse events, the NCI-CTC 3.0 was applied. Result There were 11 cases that were qualified for efficacy evaluation and 15 cases for safety evaluation. Among the 11 cases included in efficacy evaluation, there were 8 cases achieving SD and 3 cases of PD. The disease control rate was 72.2% (8/11). The safety evaluation results showed that the incidence of skin rash relat-ed to nimotuzumab was low, and which was in no association with clinical benefit. All adverse events related with nimotuzumab were mild. Conclusion Nimotuzumab combined with chemotherapy or radiotherapy for patients with NSCLC increases disease control rate and has a better safety profile.